Legend Biotech (LEGN) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Legend Biotech (LEGN) over the past year, gaining 226.6% versus a loss of 41.9%. Over five years, TNGX leads with a +60.9% price change compared with -64.0% for LEGN. Tango Therapeutics is the larger company by market cap ($3.92 billion vs $3.63 billion), about 1.1 times the size, while Legend Biotech is growing revenue faster (+64.0% vs +48.3%).
Legend Biotech converts more of its revenue into profit, with a net margin of -28.8% versus -162.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LEGN | TNGX |
|---|---|---|
| Share price | $18.67 | $23.27 |
| Market cap | $3.63B | $3.92B |
| 1-day change | -0.21% | +3.10% |
| YTD return | -13.94% | +154.74% |
| 1-year return | -41.91% | +226.63% |
| 5-year return | -63.96% | +60.87% |
| Forward P/E | 17.78 | — |
| EPS (TTM) | $-0.52 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.03B | $62.38M |
| Revenue growth (YoY) | +64.04% | +48.29% |
| Net income (latest FY) | $-296.80M | $-101.59M |
| Gross margin | 61.41% | — |
| Operating margin | -13.27% | -178.39% |
| Net margin | -28.85% | -162.85% |
| 52-week high | $37.50 | $34.39 |
| 52-week low | $16.24 | $6.69 |
| Distance from 52-week high | -50.21% | -32.33% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +149.06% | +94.16% |
| Average volume | 2.37M | 2.65M |
| Shares outstanding | 194.49M | 168.61M |
| Employees | 3,200 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed LEGN by 268.5 percentage points over the past year.
- Legend Biotech is more profitable, keeping -28.8 cents of every revenue dollar as net income versus -162.9 cents for Tango Therapeutics.
- Legend Biotech grew revenue faster in its latest fiscal year (+64.04% vs +48.29%).
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
LEGN vs TNGX FAQ
Which is bigger, Legend Biotech or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.92B compared with $3.63B for Legend Biotech (LEGN).
Which stock has performed better over the past year, LEGN or TNGX?
TNGX returned +226.63% over the past 12 months, compared with -41.91% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are Legend Biotech and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.